NASDAQ:VIR

Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023

Late-breaking data from BRII-835 + PEG-IFN-a study demonstrate anti-HBs titers at the end of treatment were associated with sustained HBsAg loss 24 weeks after the end of treatment  New data show more robust and persistent anti-HBs titers following vaccination with VBI's 3-antigen prevention vac...

2023-06-25 20:00 3658